OA01178A - Process for preparing 1,1-dioxides of 3,4-sulfamyl-1,2,4-dihydro, benzothiadiazine. - Google Patents

Process for preparing 1,1-dioxides of 3,4-sulfamyl-1,2,4-dihydro, benzothiadiazine.

Info

Publication number
OA01178A
OA01178A OA51359A OA51359A OA01178A OA 01178 A OA01178 A OA 01178A OA 51359 A OA51359 A OA 51359A OA 51359 A OA51359 A OA 51359A OA 01178 A OA01178 A OA 01178A
Authority
OA
OAPI
Prior art keywords
benzothiadiazine
sulfamyl
dioxides
dihydro
preparing
Prior art date
Application number
OA51359A
Other languages
French (fr)
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of OA01178A publication Critical patent/OA01178A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15Six-membered rings
    • C07D285/16Thiadiazines; Hydrogenated thiadiazines
    • C07D285/181,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/201,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/221,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/241,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C07D285/261,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
    • C07D285/281,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15Six-membered rings
    • C07D285/16Thiadiazines; Hydrogenated thiadiazines
    • C07D285/181,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/201,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/221,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/241,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C07D285/261,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
    • C07D285/301,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with hydrocarbon radicals, substituted by hetero atoms, attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
OA51359A 1958-03-03 1964-12-31 Process for preparing 1,1-dioxides of 3,4-sulfamyl-1,2,4-dihydro, benzothiadiazine. OA01178A (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US71845258A 1958-03-03 1958-03-03
US72724258A 1958-04-09 1958-04-09
US74058258A 1958-06-09 1958-06-09
US75162058A 1958-07-29 1958-07-29
US76448258A 1958-09-29 1958-09-29
DEC0024178 1959-02-27
DEC0028408 1959-02-27
DEC0028409 1959-02-27
DEC0024177 1959-02-27
DEC0024176 1959-02-27

Publications (1)

Publication Number Publication Date
OA01178A true OA01178A (en) 1969-01-25

Family

ID=27579177

Family Applications (2)

Application Number Title Priority Date Filing Date
OA51359A OA01178A (en) 1958-03-03 1964-12-31 Process for preparing 1,1-dioxides of 3,4-sulfamyl-1,2,4-dihydro, benzothiadiazine.
OA52080A OA03826A (en) 1958-03-03 1965-06-29 Process for the preparation of a new heterocyclic compound.

Family Applications After (1)

Application Number Title Priority Date Filing Date
OA52080A OA03826A (en) 1958-03-03 1965-06-29 Process for the preparation of a new heterocyclic compound.

Country Status (6)

Country Link
CH (4) CH371454A (en)
DE (4) DE1445005A1 (en)
FR (2) FR1217929A (en)
GB (1) GB861367A (en)
MY (1) MY6200051A (en)
OA (2) OA01178A (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3200117A (en) * 1962-10-03 1965-08-10 Hoffmann La Roche Derivatives of 1, 2, 4-benzothiadiazine-7-sulfonamide-1, 1-dioxide
DE2642140C2 (en) * 1976-09-20 1982-10-28 Degussa Ag, 6000 Frankfurt Process for the production of benzoyl cyanide
DE8700284U1 (en) * 1987-01-07 1987-04-30 Ernst Reiner GmbH & Co KG, 7743 Furtwangen Post date stamp
CA2320354A1 (en) * 1998-02-18 1999-08-26 Neurosearch A/S Novel compounds and their use as positive ampa receptor modulators
US6943159B1 (en) 1998-02-18 2005-09-13 Neurosearch A/S Compounds and their use as positive AMPA receptor modulators
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
PT1355644E (en) 2001-01-26 2006-11-30 Schering Corp The use of substituted azetidinone compounds for the treatment of sitosterolemia
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
RS20100015A (en) 2001-01-26 2010-12-31 Schering Corporation Combination of receptor activator activated by fenofibrate peroxisome-proliferator (ppar) with sterol absorption inhibitor ezetimibe for vascular indications
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
EP1429756B1 (en) 2001-09-21 2006-11-22 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
EP1545519B1 (en) 2002-08-19 2011-03-23 Pfizer Inc. Combination therapy for hyperproliferative diseases
JP2006508188A (en) 2002-11-06 2006-03-09 シェーリング コーポレイション Cholesterol absorption inhibitors for the treatment of demyelination
CN1756755A (en) 2003-03-07 2006-04-05 先灵公司 Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN1756756A (en) 2003-03-07 2006-04-05 先灵公司 Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
DE602004016123D1 (en) 2003-03-07 2008-10-09 Schering Corp SUBSTITUTED AZETIDINONE DERIVATIVES, THEIR PHARMACEUTICAL FORMULATIONS AND THEIR USE FOR THE TREATMENT OF HYPERCHOLESTEROLMIA
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
JP5498168B2 (en) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー N-((3-Benzyl) -2,2- (bis-phenyl) -propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular disease
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (en) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders.
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP2016514671A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists and uses thereof
JP2016514670A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase receptor agonists in combination with other drugs
SG11201507496UA (en) 2013-04-17 2015-11-27 Pfizer N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
EA201592263A1 (en) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. ULTRASCULAR AGONISTS OF GUANYLACYCLASE C, METHOD OF THEIR RECEIVING AND USING
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof

Also Published As

Publication number Publication date
CH371454A (en) 1963-08-31
DE1112079B (en) 1961-08-03
MY6200051A (en) 1962-12-31
CH376514A (en) 1964-04-15
DE1445005A1 (en) 1968-10-24
FR1217929A (en) 1960-05-06
DE1445007A1 (en) 1968-10-24
OA03826A (en) 1971-12-24
CH387642A (en) 1965-02-15
FR1264468A (en) 1961-06-23
DE1445006B2 (en) 1975-05-07
DE1445574A1 (en) 1969-01-16
DE1445008A1 (en) 1968-10-24
GB861367A (en) 1961-02-22
DE1445006A1 (en) 1968-10-24
CH377365A (en) 1964-05-15

Similar Documents

Publication Publication Date Title
FR1264468A (en) Process for the preparation of 1, 1-dioxides of sulfamyl-1-3, 4-dihydro-1, 2, 4-benzothiadiazine
OA01196A (en) Process for the preparation of derivatives of the 1,1-dioxide of 3,4-dihydro-1,2,4-benzothiadiazine.
BE576304A (en) Process for preparing 1,1-dioxides of sulfamyl-3,4-dihydro -1,2,4-benzothiadiazine
BE575758A (en) Process for the preparation of substituted benzothiadiazine bioxides.
FR1224766A (en) Process for preparing 1,2,4-benzothiadiazine-1,1-dioxides
FR1271046A (en) Process for preparing 1, 1-dioxides of sulfamyl-3, 4-dihydro-1, 2, 4-benzothiadiazine
BE578374A (en) Process for preparing 6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadaizine-1,1-dioxide.
FR1481002A (en) Process for the preparation of 3, 4-dihydro-1, 2. 4-benzothiadiazine-1, 1-dioxides
FR1393951A (en) Process for the preparation of compounds of the 3-oxo-3, 4-dihydro-1, 2, 4-benzothiadiazine-1, 1-dioxide type
FR1341458A (en) Process for preparing 6-chloro-7-sulfamyl-3, 4-dihydro-1, 2, 4-benzothiadiazine-1, 1-dioxide
OA01179A (en) Process for the preparation of derivatives of the 1,1-dioxide of 3,4-dihydro-1,2,4, benzothiadiazine.
BE617986A (en) Process for the preparation of 3-oxo-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxides substituted in position 2
BE591152A (en) Process for preparing 3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide derivatives
FR1264879A (en) Process for the manufacture of 3, 4-dihydro-1, 2, 4-benzothiadiazine-1, 1-dioxides
OA01373A (en) Process for the preparation of sulfonylureas.
DK126117B (en) Process for the preparation of 1,2,4-benzothiadiazine-1,1-dioxide compounds.
BE597435A (en) Process for the preparation of derivatives of the 1,1-dioxide of 3,4-dihydro-1,2,4-benzo-thiadiazine.
BE580881A (en) Process for preparing 6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide and product obtained.
FR1298925A (en) Process for preparing 3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide derivatives
FR1337762A (en) Process for the preparation of 3, 4-dihydro-1, 2, 4-benzothiadiazine-1, 1-substituted dioxides
BE583907A (en) Process for the preparation of sulfamyl-pyrido [2,3-e] -1,2,4-thiadiazines 1,1-dioxides
BE588339A (en) Process for the preparation of a derivative of 3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide
BE583943A (en) Process for the preparation of sulfamyl-3,4-dihydro-pyrido-1,2,4-thiadiazines 1,1-dioxides
FR1283826A (en) Process for the preparation of 1, 1-dioxide derivatives of 3, 4-dihydro-1, 2, 4-benzothiadiazine
BE581588A (en) 6-trifluoromethyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxides and process for their preparation.